In a groundbreaking advancement for ophthalmic care in Qatar, The View Hospital, in collaboration with Cedars-Sinai, has successfully performed the country’s first implantation of the iStent inject W, a minimally invasive device used to treat open-angle glaucoma. 

The procedure was led by Prof. Ahmad Muneer Otri, Consultant Ophthalmologist, and marks a significant step forward in the hospital’s mission to introduce cutting-edge medical technologies that improve patient outcomes across the region.

The iStent inject W is part of a new class of treatments known as Minimally Invasive Glaucoma Surgeries (MIGS). Designed for patients with mild to moderate open-angle glaucoma, the device works by enhancing the eye’s natural fluid drainage, thereby reducing intraocular pressure. This approach offers an alternative to more invasive surgeries and long-term reliance on medication.

In the case performed at The View Hospital, the patient experienced a smooth recovery, with normalized eye pressure and full restoration of vision, and was discharged without the need for extended hospitalization. 

Clinical studies have shown that the iStent inject W is both safe and effective, offering reduced intraocular pressure and medication dependence across various glaucoma severities. 

This milestone reflects a broader transformation in Qatar’s healthcare landscape, where precision-driven, preventative care is becoming the norm. For glaucoma patients, it signals earlier intervention, fewer complications, and a better quality of life.

The View Hospital continues to position itself as a regional leader in advanced eye care, reinforcing its reputation as a center of excellence in ophthalmology.